CY1111757T1 - Παραγωγα ξανθινης ως εκλεκτικοι αναστολεις ημ74α - Google Patents
Παραγωγα ξανθινης ως εκλεκτικοι αναστολεις ημ74αInfo
- Publication number
- CY1111757T1 CY1111757T1 CY20111100033T CY111100033T CY1111757T1 CY 1111757 T1 CY1111757 T1 CY 1111757T1 CY 20111100033 T CY20111100033 T CY 20111100033T CY 111100033 T CY111100033 T CY 111100033T CY 1111757 T1 CY1111757 T1 CY 1111757T1
- Authority
- CY
- Cyprus
- Prior art keywords
- hm74a
- xanthini
- products
- compounds
- suspensions
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
- C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
Abstract
Η παρούσα εφεύρεση αφορά ενώσεις του τύπου (I) που είναι παράγωγα ξανθίνης, μεθόδους για τη βιομηχανική κατασκευή των εν λόγω παραγώγων, φαρμακοτεχνικές μορφές που περιέχουν αυτές τις ενώσεις και τη χρήση των ενώσεων στη θεραπεία, για παράδειγμα, στη θεραπεία ασθενειών όπου υπο-ενεργοποίηση του υποδοχέα ΗΜ74Α συνεισφέρει στην ασθένεια ή όπου η ενεργοποίηση του υποδοχέα θα είναι ευεργετική.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0516464A GB0516464D0 (en) | 2005-08-10 | 2005-08-10 | Novel compounds |
GB0607736A GB0607736D0 (en) | 2006-04-19 | 2006-04-19 | Novel compounds |
GB0614569A GB0614569D0 (en) | 2006-07-21 | 2006-07-21 | Novel compounds |
EP06763016A EP1912991B1 (en) | 2005-08-10 | 2006-08-08 | Xanthine derivatives as selective hm74a agonists |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1111757T1 true CY1111757T1 (el) | 2015-10-07 |
Family
ID=37189397
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20111100033T CY1111757T1 (el) | 2005-08-10 | 2011-01-12 | Παραγωγα ξανθινης ως εκλεκτικοι αναστολεις ημ74α |
Country Status (29)
Country | Link |
---|---|
US (3) | US20100179128A1 (el) |
EP (3) | EP2272848B1 (el) |
JP (2) | JP2009504592A (el) |
KR (2) | KR20080034993A (el) |
AR (1) | AR055369A1 (el) |
AT (1) | ATE487719T1 (el) |
AU (2) | AU2006278216A1 (el) |
BR (2) | BRPI0615145A2 (el) |
CA (2) | CA2626723A1 (el) |
CR (2) | CR9748A (el) |
CY (1) | CY1111757T1 (el) |
DE (1) | DE602006018151D1 (el) |
DK (1) | DK1912991T3 (el) |
EA (2) | EA200800564A1 (el) |
ES (1) | ES2401128T3 (el) |
HK (1) | HK1116779A1 (el) |
HR (1) | HRP20100725T1 (el) |
IL (2) | IL189083A0 (el) |
MA (2) | MA29693B1 (el) |
MX (2) | MX2008001929A (el) |
MY (1) | MY142067A (el) |
NO (2) | NO20081212L (el) |
NZ (1) | NZ565494A (el) |
PE (1) | PE20070405A1 (el) |
PL (1) | PL1912991T3 (el) |
PT (1) | PT1912991E (el) |
SI (1) | SI1912991T1 (el) |
TW (1) | TW200800217A (el) |
WO (2) | WO2007017261A1 (el) |
Families Citing this family (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7495005B2 (en) * | 2002-08-22 | 2009-02-24 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Xanthine derivatives, their preparation and their use in pharmaceutical compositions |
BRPI0507604A (pt) * | 2004-02-14 | 2007-07-03 | Smithkline Beecham Corp | medicamentos com atividade de receptor hm74a |
DE102004030502A1 (de) | 2004-06-24 | 2006-01-12 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Imidazole und Triazole, deren Herstellung und Verwendung als Arzneimittel |
DE602006018151D1 (de) * | 2005-08-10 | 2010-12-23 | Glaxosmithkline Llc | Xanthinderivate als selektive hm74a-agonisten |
AR061626A1 (es) | 2006-06-23 | 2008-09-10 | Incyte Corp | Derivados de purinona como agonistas de hm74a |
CN101466714B (zh) | 2006-06-23 | 2013-02-06 | 英赛特股份有限公司 | 作为hm74a激动剂的嘌呤酮衍生物 |
BRPI0715160A2 (pt) | 2006-08-08 | 2013-06-11 | Sanofi Aventis | imidazolidina-2,4-dionas substituÍdas por arilamimoaril-alquil-, processo para preparÁ-las, medicamentos compeendendo estes compostos, e seu uso |
EP2025674A1 (de) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
DE102007063671A1 (de) | 2007-11-13 | 2009-06-25 | Sanofi-Aventis Deutschland Gmbh | Neue kristalline Diphenylazetidinonhydrate, diese Verbindungen enthaltende Arzneimittel und deren Verwendung |
EP2310372B1 (en) | 2008-07-09 | 2012-05-23 | Sanofi | Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof |
WO2010068601A1 (en) | 2008-12-08 | 2010-06-17 | Sanofi-Aventis | A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof |
CN102245606B (zh) | 2008-12-08 | 2014-08-20 | 葛兰素史密斯克莱有限责任公司 | 新化合物 |
BR112012003973A2 (pt) | 2009-08-26 | 2015-09-08 | Sanofi Sa | hidratos de fluoroglicosídeo heteroaromático cristalinos, produtos farmacêuticos compreendendo estes compostos e seu uso |
WO2011107494A1 (de) | 2010-03-03 | 2011-09-09 | Sanofi | Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
KR101799429B1 (ko) * | 2010-05-03 | 2017-11-21 | 에스케이바이오팜 주식회사 | 신경 세포 사멸 또는 신경 퇴화를 억제하기 위한 약학적 조성물 |
WO2011157827A1 (de) | 2010-06-18 | 2011-12-22 | Sanofi | Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen |
US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
TW201215388A (en) | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
JP5619284B2 (ja) * | 2010-08-16 | 2014-11-05 | ベーリンガーインゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | ロイコトリエン産生のオキサジアゾール阻害薬 |
US8580825B2 (en) * | 2010-09-23 | 2013-11-12 | Boehringer Ingelheim International Gmbh | Oxadiazole inhibitors of leukotriene production |
WO2012120053A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
WO2012120056A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
US8710050B2 (en) | 2011-03-08 | 2014-04-29 | Sanofi | Di and tri- substituted oxathiazine derivatives, method for the production, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof |
EP2683705B1 (de) | 2011-03-08 | 2015-04-22 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
US8901114B2 (en) | 2011-03-08 | 2014-12-02 | Sanofi | Oxathiazine derivatives substituted with carbocycles or heterocycles, method for producing same, drugs containing said compounds, and use thereof |
WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
WO2013045413A1 (en) | 2011-09-27 | 2013-04-04 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
WO2013178572A1 (en) * | 2012-05-30 | 2013-12-05 | F. Hoffmann-La Roche Ag | Triazolo compounds as pde10 inhibitors |
MY189912A (en) * | 2013-03-15 | 2022-03-21 | Hydra Biosciences Llc | Substituted xanthines and methods of use thereof |
KR20160005364A (ko) | 2013-05-10 | 2016-01-14 | 님버스 아폴로, 인코포레이티드 | Acc 억제제 및 이의 용도 |
JP6434498B2 (ja) | 2013-05-10 | 2018-12-05 | ギリアド アポロ, エルエルシー | Acc阻害剤及びその使用 |
MX2015015416A (es) | 2013-05-10 | 2016-06-21 | Nimbus Apollo Inc | Inhibidores de acetil-coa carboxilasa (acc) y usos de los mismos. |
KR20160007598A (ko) * | 2013-05-10 | 2016-01-20 | 님버스 아폴로, 인코포레이티드 | Acc 억제제 및 이의 용도 |
CN104211702B (zh) * | 2013-05-29 | 2018-08-31 | 中国医学科学院药物研究所 | 取代黄嘌呤类化合物及其制备方法和用途 |
CN105646492B (zh) * | 2014-11-14 | 2019-04-09 | 中国医学科学院药物研究所 | 含五元芳杂环的取代黄嘌呤类化合物及其制备方法和用途 |
DE102017000359A1 (de) | 2016-08-26 | 2018-03-01 | Bihl+Wiedemann Gmbh | Diagnose-Repeater für AS-Interface Netze |
CN114874209A (zh) * | 2017-03-07 | 2022-08-09 | 豪夫迈·罗氏有限公司 | 噁二唑瞬时受体电位通道抑制剂 |
CN112724141A (zh) * | 2021-01-21 | 2021-04-30 | 南京艾美斐生物医药科技有限公司 | 一种gpr109a蛋白受体抑制剂及其制备和应用 |
TW202342465A (zh) * | 2022-02-03 | 2023-11-01 | 美商D E 蕭爾研究有限公司 | 作為trpa1抑制劑之n3經取代脲嘧啶化合物 |
Family Cites Families (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2797220A (en) | 1954-12-02 | 1957-06-25 | Univ Michigan | Substituted paraxanthines |
GB8906792D0 (en) | 1989-03-23 | 1989-05-10 | Beecham Wuelfing Gmbh & Co Kg | Treatment and compounds |
NZ240644A (en) | 1990-11-21 | 1994-08-26 | Smithkline Beecham Corp | Use of xanthine derivatives to inhibit the production of tumour necrosis factor (tnf) |
AU3725893A (en) | 1992-02-21 | 1993-09-13 | Smithkline Beecham Corporation | TNF inhibitors |
ATE230990T1 (de) | 1992-03-04 | 2003-02-15 | Cell Therapeutics Inc | Enantiomere hydroxylierte xanthinverbindungen |
US5780476A (en) | 1992-11-16 | 1998-07-14 | Cell Therapeutics, Inc. | Hydroxyl-containing xanthine compounds |
US5473070A (en) | 1992-11-16 | 1995-12-05 | Cell Therapeutics, Inc. | Substituted long chain alcohol xanthine compounds |
US6469017B1 (en) | 1998-01-16 | 2002-10-22 | Cell Therapeutics, Inc. | Method of inhibiting interleukin-12 signaling |
US6693105B1 (en) | 1992-11-16 | 2004-02-17 | Cell Therapeutics, Inc. | Hydroxyl-containing compounds |
IL109161A0 (en) | 1993-03-31 | 1994-06-24 | Cell Therapeutics Inc | Amino alcohol derivatives, methods for the preparation thereof, and pharmaceutical compositions containing the same |
US5670506A (en) | 1993-04-05 | 1997-09-23 | Cell Therapeutics, Inc. | Halogen, isothiocyanate or azide substituted xanthines |
WO1994024133A1 (en) | 1993-04-09 | 1994-10-27 | Cell Therapeutics, Inc. | Ring-substituted cell signaling inhibitors |
WO1995020589A1 (en) | 1994-01-28 | 1995-08-03 | Cell Therapeutics, Inc. | Cell signaling inhibitors |
US6103730A (en) | 1994-03-24 | 2000-08-15 | Cell Therapeutics, Inc. | Amine substituted compounds |
US6780865B1 (en) | 1994-02-18 | 2004-08-24 | Cell Therapeutics, Inc. | Compounds having selective hydrolytic potentials |
US6878715B1 (en) | 1994-02-18 | 2005-04-12 | Cell Therapeutics, Inc. | Therapeutic compounds for inhibiting interleukin-12 signals and method for using same |
WO1995022546A1 (en) | 1994-02-18 | 1995-08-24 | Cell Therapeutics, Inc. | Intracellular signalling mediators |
US5807861A (en) | 1994-03-24 | 1998-09-15 | Cell Therapeutics, Inc. | Amine substituted xanthinyl compounds |
US6323201B1 (en) * | 1994-12-29 | 2001-11-27 | The Regents Of The University Of California | Compounds for inhibition of ceramide-mediated signal transduction |
AR015966A1 (es) | 1997-10-17 | 2001-05-30 | Smithkline Beecham Corp | Uso de un compuesto inhibidor de pde4 para la preparacion de un medicamento util para el tratamiento de prurito |
MXPA01010143A (es) | 1999-04-09 | 2003-07-14 | Cell Therapeutics Inc | Derivados de xantina y analogos como inhibidores de transmision de senales celulares. |
US20030207901A1 (en) | 1999-07-27 | 2003-11-06 | Cell Therapeutics, Inc. | Hydroxyl-containing compounds |
US6821978B2 (en) | 2000-09-19 | 2004-11-23 | Schering Corporation | Xanthine phosphodiesterase V inhibitors |
US6586429B2 (en) * | 2000-11-29 | 2003-07-01 | Cell Therapeutics, Inc. | Tricyclic fused xanthine compounds and their uses |
KR100883277B1 (ko) | 2001-02-24 | 2009-02-12 | 베링거 잉겔하임 파르마 게엠베하 운트 코 카게 | 크산틴 유도체 및 이의 제조방법 |
US20040254224A1 (en) | 2001-04-11 | 2004-12-16 | Foord Steven Michael | Medicaments |
ATE388951T1 (de) * | 2001-07-03 | 2008-03-15 | Novo Nordisk As | Dpp-iv-inhibierende purin-derivative zur behandlung von diabetes |
DE60304911D1 (de) | 2002-02-25 | 2006-06-08 | Eisai Co Ltd | Xanthin-Derivate als DPP-IV-Inhibitoren |
US7482337B2 (en) | 2002-11-08 | 2009-01-27 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions |
CN1227492C (zh) * | 2003-03-11 | 2005-11-16 | 张跃 | 一种吸收式空调主体 |
GB0319124D0 (en) * | 2003-08-14 | 2003-09-17 | Smithkline Beecham Corp | Chemical compounds |
BRPI0507604A (pt) | 2004-02-14 | 2007-07-03 | Smithkline Beecham Corp | medicamentos com atividade de receptor hm74a |
WO2006045564A1 (en) | 2004-10-22 | 2006-05-04 | Smithkline Beecham Corporation | Xanthine derivatives with hm74a receptor activity |
JP2008517029A (ja) * | 2004-10-22 | 2008-05-22 | スミスクライン・ビーチャム・コーポレイション | Hm74a受容体活性を有するキサンチン誘導体 |
US20090209561A1 (en) * | 2004-10-22 | 2009-08-20 | Richard Jonathan Daniel Hatley | Xanthine Derivatives with HM74A Receptor Activity |
WO2006085112A1 (en) | 2005-02-14 | 2006-08-17 | Smithkline Beecham Corporation | Anthranilic acid derivatives as hm74a receptor agonists |
GB0516462D0 (en) * | 2005-08-10 | 2005-09-14 | Smithkline Beecham Corp | Novel compounds |
DE602006018151D1 (de) * | 2005-08-10 | 2010-12-23 | Glaxosmithkline Llc | Xanthinderivate als selektive hm74a-agonisten |
DE102008009758A1 (de) * | 2008-02-18 | 2009-08-20 | Beiersdorf Ag | Verwendung von 3-(4-Hydroxy-3-methoxyphenyl)-1-(4-hydroxyphenyl)-propan-1-on zur verbesserten Hautkonturierung bzw. gegen Cellulite |
CN102245606B (zh) | 2008-12-08 | 2014-08-20 | 葛兰素史密斯克莱有限责任公司 | 新化合物 |
-
2006
- 2006-08-08 DE DE602006018151T patent/DE602006018151D1/de active Active
- 2006-08-08 EP EP10172674A patent/EP2272848B1/en active Active
- 2006-08-08 ES ES10172674T patent/ES2401128T3/es active Active
- 2006-08-08 KR KR1020087005717A patent/KR20080034993A/ko not_active Application Discontinuation
- 2006-08-08 EP EP06763016A patent/EP1912991B1/en active Active
- 2006-08-08 SI SI200630916T patent/SI1912991T1/sl unknown
- 2006-08-08 AT AT06763016T patent/ATE487719T1/de active
- 2006-08-08 WO PCT/EP2006/007865 patent/WO2007017261A1/en active Application Filing
- 2006-08-08 EA EA200800564A patent/EA200800564A1/ru unknown
- 2006-08-08 US US12/063,432 patent/US20100179128A1/en not_active Abandoned
- 2006-08-08 PE PE2006000963A patent/PE20070405A1/es not_active Application Discontinuation
- 2006-08-08 CA CA002626723A patent/CA2626723A1/en not_active Abandoned
- 2006-08-08 DK DK06763016.0T patent/DK1912991T3/da active
- 2006-08-08 AU AU2006278216A patent/AU2006278216A1/en not_active Abandoned
- 2006-08-08 CA CA002618963A patent/CA2618963A1/en not_active Abandoned
- 2006-08-08 EA EA200800555A patent/EA014556B1/ru not_active IP Right Cessation
- 2006-08-08 MY MYPI20063833A patent/MY142067A/en unknown
- 2006-08-08 US US12/063,434 patent/US8143264B2/en not_active Expired - Fee Related
- 2006-08-08 WO PCT/EP2006/007869 patent/WO2007017262A1/en active Application Filing
- 2006-08-08 TW TW095128952A patent/TW200800217A/zh unknown
- 2006-08-08 MX MX2008001929A patent/MX2008001929A/es not_active Application Discontinuation
- 2006-08-08 NZ NZ565494A patent/NZ565494A/en not_active IP Right Cessation
- 2006-08-08 PT PT06763016T patent/PT1912991E/pt unknown
- 2006-08-08 BR BRPI0615145-0A patent/BRPI0615145A2/pt not_active Application Discontinuation
- 2006-08-08 AU AU2006278215A patent/AU2006278215A1/en not_active Abandoned
- 2006-08-08 KR KR1020087005724A patent/KR20080038396A/ko not_active Application Discontinuation
- 2006-08-08 EP EP06776699A patent/EP1912992A1/en not_active Withdrawn
- 2006-08-08 PL PL06763016T patent/PL1912991T3/pl unknown
- 2006-08-08 JP JP2008525475A patent/JP2009504592A/ja not_active Withdrawn
- 2006-08-08 JP JP2008525474A patent/JP5112316B2/ja not_active Expired - Fee Related
- 2006-08-08 MX MX2008001931A patent/MX2008001931A/es active IP Right Grant
- 2006-08-08 AR ARP060103459A patent/AR055369A1/es unknown
- 2006-08-08 BR BRPI0614270-2A patent/BRPI0614270A2/pt not_active IP Right Cessation
-
2008
- 2008-01-28 IL IL189083A patent/IL189083A0/en unknown
- 2008-01-28 IL IL189081A patent/IL189081A0/en unknown
- 2008-02-08 MA MA30629A patent/MA29693B1/fr unknown
- 2008-02-08 MA MA30628A patent/MA29692B1/fr unknown
- 2008-02-21 CR CR9748A patent/CR9748A/es not_active Application Discontinuation
- 2008-02-21 CR CR9749A patent/CR9749A/es not_active Application Discontinuation
- 2008-03-07 NO NO20081212A patent/NO20081212L/no not_active Application Discontinuation
- 2008-03-07 NO NO20081211A patent/NO20081211L/no not_active Application Discontinuation
- 2008-07-08 HK HK08107505.5A patent/HK1116779A1/xx not_active IP Right Cessation
-
2010
- 2010-12-27 HR HR20100725T patent/HRP20100725T1/hr unknown
-
2011
- 2011-01-12 CY CY20111100033T patent/CY1111757T1/el unknown
- 2011-04-18 US US13/088,962 patent/US20110257205A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1111757T1 (el) | Παραγωγα ξανθινης ως εκλεκτικοι αναστολεις ημ74α | |
CY1122646T1 (el) | Δικυκλικες ετεροαρυλ ενωσεις | |
CY1122218T1 (el) | Αλατα και πολυμορφα της 8-φθορο-2-{4-[(μεθυλαμινο)μεθυλο]φαινυλο}-1,3,4,5-τετραϋδρο-6η-αζεπινο[5,4,3-cd]ινδολο-6-ονης | |
CY1115836T1 (el) | Παραγωγα πυραζινονης και η χρηση τους στη θεραπευτικη αντιμετωπιση παθησεων των πνευμονων | |
CY1107426T1 (el) | Νεα παραγωγα φθοριογλυκοσιδιων απο πυραζολες, φαρμακευτικα προϊοντα που περιεχουν τις εν λογω ενωσεις και η χρηση αυτων | |
CY1111903T1 (el) | Σπειροκυκλικα παραγωγα κυκλοεξανιου με αναλγητικη δραση | |
CY1117319T1 (el) | Τρικυκλικα παραγωγα αμινης ως αναστολεις πρωτεϊνικης τυροσινης κινασης | |
CY1116700T1 (el) | Παρασκευη συνθετικου χολικου οξεος | |
CY1116156T1 (el) | Παραγωγα πυριμιδινης συνδεδεμενα με οξυγονο | |
CY1116929T1 (el) | Παραγωγα πυρρολο[2,3-d]πυριμιδινης ως αναστολεις πρωτεϊνικης κινασης β | |
ATE316077T1 (de) | Pyrimidin-essigsäure derivate geeignet zur behandlung von crth2-bedingten krankheiten | |
CY1114022T1 (el) | Φαρμακα με δραση υποδοχεα ημ74α | |
CY1114872T1 (el) | Συνθεσεις και μεθοδοι χρησης αντισωματων εναντι της σκληροστεϊνης | |
CY1105962T1 (el) | Υποκατεστημενα παραγωγα διοξειδιου θειαζολο-βενζοϊσοθειαζολιου, μεθοδος για την παραγωγη αυτων και η χρηση αυτων | |
CY1109696T1 (el) | Υποκατεστημενα παραγωγα πυριδινυλιου και πυριμιδινυλιου ως διαμορφωτες του μεταβολισμου και η θεραπεια των σχετικων με αυτον διαταραχων | |
CY1112495T1 (el) | Κυτταροτοξικοι παραγοντες που περιλαμβανουν νεα παραγωγα τομαϋμυκινης | |
CY1110965T1 (el) | Επιπροσθετες ετεροπολυκυκλικες ενωσεις και η χρηση τους ως ανταγωνιστες μεταβολοτροπικου υποδοχεα γλουταμικου | |
CY1106476T1 (el) | Υποκατεστημενες διυδροκιναζολινες με αντι-ιικες ιδιοτητες | |
CY1105621T1 (el) | Νεα ετεροκυκλικα παραγωγα φθορογλυκοζιτου, φαρμακα που περιεχουν τις ενωσεις αυτες και η χρηση τους | |
NO20060230L (no) | Nye aminobenzofenonforbindelser | |
EA200701930A1 (ru) | Производные пиримидина для лечения гиперпролиферативных нарушений | |
CY1110190T1 (el) | Παραγωγα πιπεραζινυλιου χρησιμα στην αγωγη των νοσων στις οποιες μεσολαβει ο υποδοχεας gpr38 | |
CY1113257T1 (el) | Παραγωγα βενζυλοπιπεραζινης τα οποια ειναι χρησιμα στη θεραπεια γαστρεντερικων διαταραχων | |
BRPI0407234A (pt) | Heterociclos substituìdos | |
CY1113533T1 (el) | Ετεροαρυλο-υποκατεστημενα παραγωγα κυκλοεξυλο-1,4-διαμινης |